- Home
- ASO vs KNSA Comparison
ASO vs KNSA Comparison
Compare ASO & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASO | KNSA |
|---|---|---|
| Founded | 1938 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.5B |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ASO | KNSA |
|---|---|---|
| Price | $57.89 | $42.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $58.08 | $56.00 |
| AVG Volume (30 Days) | ★ 1.3M | 547.5K |
| Earning Date | 06-09-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | ★ 5.54 | 0.75 |
| Revenue | ★ $6,053,414,000.00 | $677,564,000.00 |
| Revenue This Year | $5.13 | $37.60 |
| Revenue Next Year | $5.36 | $17.77 |
| P/E Ratio | ★ $10.46 | $57.07 |
| Revenue Growth | 2.02 | ★ 60.09 |
| 52 Week Low | $35.95 | $20.24 |
| 52 Week High | $62.45 | $50.03 |
Technical Indicators
Market Signals| Indicator | ASO | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 53.86 | 32.66 |
| Support Level | $57.09 | $41.98 |
| Resistance Level | $60.55 | $42.91 |
| Average True Range (ATR) | 2.47 | 1.97 |
| MACD | 0.26 | -0.66 |
| Stochastic Oscillator | 57.66 | 10.07 |
Price Performance
Historical ComparisonAbout ASO Academy Sports and Outdoors Inc.
Academy Sports and Outdoors Inc is engaged in the full-line sporting goods and outdoor recreation retailer in the United States. The company's product categories are outdoors, apparel, sports & recreation, and footwear.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.